Rational design, synthesis and pharmacological characterization of novel aminopeptidase A inhibitors
Fabrice Balavoine1, Delphine Compere2, Frédéric Miege3
1Quantum Genomics, 6 rue Cambacérès, F-75008 Paris, France.
Abstract:
Aminopeptidase A (APA) is a membrane-bound zinc metallopeptidase involved in the production of angiotensin III, one effector peptide of the brain renin-angiotensin system, making brain APA a relevant pharmacological target for the development of novel therapeutic treatments against hypertension and heart failure. The structure-based design of new APA inhibitors is described, based on previously developed thiol-containing inhibitors and APA crystal structure. Chemical synthesis, in vitro assessment against APA activity, pharmacological and pharmacokinetic profiling were performed, ultimately leading to a potent and selective APA inhibitor.


